Beta-Blocker Use in Patients with Complete Heart Block and a Pacemaker

Benefits and Rationale

The American College of Cardiology recommends beta-blockers for all patients with current or prior symptoms of heart failure with reduced ejection fraction to reduce morbidity and mortality, with a Class I, Level of Evidence A recommendation 1
Beta-blockers improve survival and reduce hospitalizations in patients with heart failure and reduced ejection fraction, regardless of pacemaker status 1
The presence of a functioning pacemaker eliminates the primary concern about bradycardia or heart block that would otherwise be a contraindication to beta-blocker therapy 2, 3

For heart failure patients, use one of the three beta-blockers proven to reduce mortality: Bisoprolol, Carvedilol, or Sustained-release metoprolol succinate, as recommended by the American Heart Association 1, 4, 5
Carvedilol may provide greater benefit than metoprolol in patients with heart failure, as it has both beta-blocking and alpha-adrenergic-blocking effects 4, 5

Start with a very low dose and titrate gradually: Bisoprolol (1.25 mg daily, target 10 mg daily), Metoprolol succinate CR (12.5-25 mg daily, target 200 mg daily), or Carvedilol (3.125 mg twice daily, target 25-50 mg twice daily) 5, 6
Titrate the dose every 1-2 weeks if the preceding dose was well tolerated, and monitor for potential side effects during titration, such as hypotension, fluid retention, and fatigue 2, 6

The presence of a functioning pacemaker mitigates the risk of bradycardia and heart block, which are typical concerns with beta-blocker therapy, as stated by the American Heart Association 2, 3

Regular monitoring should include heart rate, blood pressure, signs of worsening heart failure, and symptoms of hypotension, as recommended by the European Society of Cardiology 2, 5
If fluid retention occurs, increase the dose of diuretics rather than discontinuing the beta-blocker, and if hypotension occurs, consider reducing the dose of vasodilators before reducing the beta-blocker dose 2, 6

Do not discontinue beta-blockers abruptly as this can lead to clinical deterioration, and beta-blockers should be temporarily withheld during acute decompensated heart failure requiring inotropic support, but should be reintroduced before discharge once the patient is stabilized, as recommended by the American College of Cardiology 2, 3